AR177: Began Phase I open label trial in HIV-positive patients to determine safety, action and pharmacokinetics at single, escalating doses (see Other Research

Aronex Pharmaceuticals Inc. (ARNX), The Woodlands, Texas Product: AR177, oligonucleotide that inhibits HIV integrase, the viral enzyme that integrates viral DNA into human cellular DNA, and also inhi...